Inventors
Horacio G. Nastri, Needham, MA
Assignees
Merck Patent GmbH, Darmstadt (DE)
Abstract
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.